Identification of sequences required for inhibition of oncogene-mediated transformation by pp32

被引:49
作者
Brody, JR [1 ]
Kadkol, SS [1 ]
Mahmoud, MA [1 ]
Rebel, JMJ [1 ]
Pasternack, GR [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA
关键词
D O I
10.1074/jbc.274.29.20053
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oncogenic potential in prostate cancer is modulated in part by alternative use of genes of the pp32 family. This family includes the tumor suppressor pp32, expressed in normal tissue, and the pro-oncogenic genes pp32r1 and pp32r2 that are found principally in neoplastic cells. At the protein level, pp32, pp32r1, and pp32r2 are approximately 90% identical, yet they subsume opposite functions. In this study, we identify the region of pp32 associated with the ability to inhibit oncogene-mediated transformation in a rat embryo fibroblast system, an in vitro correlate of tumor-suppressive activity. Deletion and truncation analysis define a region spanning pp32 amino acids 150-174 as absolutely required for inhibition of transformed foci elicited by RAS and MYC, Comparison of pp32 with the pp32r1 sequence by moving averages of sequence identity reveals divergence over this region; pp32r2 also differs in this region through truncation after pp32 amino acid 131. The deletion experiments and the experiments of nature therefore converge to demonstrate that tumor-suppressive functions of pp32 reside in amino acids 150-174, Identification of this minimal tumor-suppressive region should help elaborate the pathways and mechanisms through which pp32 family members exert their functions.
引用
收藏
页码:20053 / 20055
页数:3
相关论文
共 10 条
  • [1] Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci
    Chen, TH
    Brody, JR
    Romantsev, RE
    Yu, JG
    Kayler, AE
    Voneiff, E
    Kuhajda, FP
    Pasternack, GR
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1996, 7 (12) : 2045 - 2056
  • [2] pp32 overexpression induces nuclear pleomorphism in rat prostatic carcinoma cells
    Gusev, Y
    Romantsev, FE
    Chen, TTH
    Kayler, AE
    Kuhajda, FP
    Dooley, WC
    Pasternack, GR
    [J]. CELL PROLIFERATION, 1996, 29 (12) : 643 - 653
  • [3] Modulation of oncogenic potential by alternative gene use in human prostate cancer
    Kadkol, SS
    Brody, JR
    Pevsner, J
    Bai, JN
    Pasternack, GR
    [J]. NATURE MEDICINE, 1999, 5 (03) : 275 - 279
  • [4] Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO
  • [5] 2-F
  • [6] KADKOL SS, 1996, CANC MOL BIOL, V3, P791
  • [7] TUMORIGENIC CONVERSION OF PRIMARY EMBRYO FIBROBLASTS REQUIRES AT LEAST 2 COOPERATING ONCOGENES
    LAND, H
    PARADA, LF
    WEINBERG, RA
    [J]. NATURE, 1983, 304 (5927) : 596 - 602
  • [8] Molecular identification of I-1(PP2A), a novel potent heat-stable inhibitor protein of protein phosphatase 2A
    Li, M
    Makkinje, A
    Damuni, Z
    [J]. BIOCHEMISTRY, 1996, 35 (22) : 6998 - 7002
  • [9] MALEK SN, 1990, J BIOL CHEM, V265, P13400
  • [10] WALENSKY LD, 1993, CANCER RES, V53, P4720